ClinicalTrials.gg
TerminatedNCT03723551Updated Sep 9, 2026Results posted

Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus

A Phase 2 interventional study of Afabicin and Cefazolin in Bone or Joint Infection, sponsored by Debiopharm International SA. Terminated at 19 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 2, Interventional, and Treatment

Why this study was terminated
This trial was concluded for strategic reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, active-controlled, open-label study to assess the safety, tolerability and efficacy of Afabicin in the treatment of participants with bone or joint infection due to Staphylococcus aureus [both methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)] and/or coagulase-negative staphylococci (CoNS) and to compare it to standard of care (SoC).

02

Conditions studied

  • Bone or Joint Infection
03

In context

Lead sponsor

Debiopharm International SA is the lead sponsor of 51 studies on the registry; 6 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able to provide written and to comply with study procedures.
  • Diagnosis of bone or joint infection which fulfils the following conditions: a) Infection is due to S. aureus (MSSA or MRSA) and/or CoNS only; and, b) Participants had received no more than 7 days of empiric antibiotics prior to initiating treatment with study drug unless the pathogen isolated was resistant to the administered empiric antibiotics; and, c) Biofilm is not considered to be yet established and/or has been mechanically eradicated; and, d) Infection is not associated with an ischiatic or a sacral osteomyelitis; and e) Infection can involve periosteal or soft tissue.

Key Exclusion Criteria:

  • Presence of co-infection with non-staphylococcal bacteria at the affected joint or bone site, or in the blood.
  • Participants at an increased risk of developing liver injury.
  • Participants who have medical conditions that increase the risk of .
  • Medical history within the previous 3 months of: myocardial infarction, unstable angina pectoris, coronary artery or cerebral revascularization procedure or stroke, ventricular tachycardia, multifocal ventricular ectopics requiring treatment, or any other symptomatic ventricular arrhythmias.
  • Documented history of alcohol or drug abuse within the previous 12 months.
  • For patients with DFO:

    1. Severe peripheral arterial disease (PAD) requiring revascularization; however, patients with peripheral artery disease are eligible for inclusion, provided they have undergone successful revascularization or it has been deemed unnecessary by a vascular surgeon
    2. Necrotizing fasciitis or gangrene requiring complete lower extremity amputation (of all infected bone and soft tissue).
    3. Patients with Charcot foot (suspected neuro-osteoarthropathy according to Investigator's judgment).
    4. Need for digital amputation.
  • of less than 1 year.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Part A: Afabicin: Cohort 1

    Participants received afabicin intravenously (IV) at a dose of 160 milligrams (mg), twice daily (BID), followed by a switch to oral afabicin at a dose of 240 mg, BID, for 2-3 weeks.

    Drug: Afabicin

  • Experimental
    Part A: Afabicin: Cohort 2

    Participants received afabicin IV at a dose of 160 mg, BID, followed by a switch to oral afabicin at a dose of 240 mg, BID, for 3-6 weeks.

    Drug: Afabicin

  • Active comparator
    Part A: SoC: Cohort 1

    Participants with oxacillin-/methicillin-susceptible staphylococci were administered with either cefazolin or vancomycin or linezolid or clindamycin, IV or linezolid or clindamycin, orally; participants with oxacillin-/methicillin-resistant staphylococci were administered either vancomycin or clindamycin or linezolid, IV or linezolid or clindamycin, orally, as part of SoC in accordance with local practice and applicable treatment guidelines without exceeding the maximum dosing schedule.

    Drug: Cefazolin · Drug: Vancomycin · Drug: Linezolid · Drug: Clindamycin

  • Active comparator
    Part A: SoC: Cohort 2

    Participants with oxacillin-/methicillin-susceptible staphylococci were administered with either cefazolin or vancomycin or linezolid or clindamycin, IV or linezolid or clindamycin, orally; participants with oxacillin-/methicillin-resistant staphylococci were administered either vancomycin or clindamycin or linezolid, IV or linezolid or clindamycin, orally, as part of SoC in accordance with local practice and applicable treatment guidelines without exceeding the maximum dosing schedule.

    Drug: Cefazolin · Drug: Vancomycin · Drug: Linezolid · Drug: Clindamycin

  • Experimental
    Part B: Afabicin: Cohort 1

    Participants received afabicin IV at a dose of 55 mg, BID, followed by a switch to oral afabicin at a dose of 80 mg, BID, for 2-3 weeks.

    Drug: Afabicin

  • Experimental
    Part B: Afabicin: Cohort 2

    Participants received afabicin IV at a dose of 55 mg, BID, followed by a switch to oral afabicin at a dose of 80 mg, BID, for 3-6 weeks.

    Drug: Afabicin

  • Active comparator
    Part B: SoC: Cohort 1

    Participants with oxacillin-/methicillin-susceptible staphylococci were administered with either cefazolin or vancomycin or linezolid or clindamycin, IV or linezolid or clindamycin, orally; participants with oxacillin-/methicillin-resistant staphylococci were administered either vancomycin or clindamycin or linezolid, IV or linezolid or clindamycin, orally, as part of SoC in accordance with local practice and applicable treatment guidelines without exceeding the maximum dosing schedule.

    Drug: Cefazolin · Drug: Vancomycin · Drug: Linezolid · Drug: Clindamycin

  • Active comparator
    Part B: SoC: Cohort 2

    Participants with oxacillin-/methicillin-susceptible staphylococci were administered with either cefazolin or vancomycin or linezolid or clindamycin, IV or linezolid or clindamycin, orally; participants with oxacillin-/methicillin-resistant staphylococci were administered either vancomycin or clindamycin or linezolid, IV or linezolid or clindamycin, orally, as part of SoC in accordance with local practice and applicable treatment guidelines without exceeding the maximum dosing schedule.

    Drug: Cefazolin · Drug: Vancomycin · Drug: Linezolid · Drug: Clindamycin

Interventions

  • Administered intravenously and orally.

  • Administered intravenously.

  • Administered intravenously.

  • Administered intravenously and orally.

  • Administered intravenously and orally.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. TEAE is any undesirable event either not present prior to medical treatment or worsening (in intensity or frequency) following treatment. SAE is defined as any untoward medical occurrence that at any dose: results in death; is life-threatening (i.e., puts the patient at immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect, or is otherwise medically significant.

    Time frame: Up to Day 142

  2. Number of Participants With Grade Shift From Baseline in Hematology Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 4.03

    Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.

    Time frame: Up to Day 142

  3. Number of Participants With Grade Shift From Baseline in Clinical Chemistry Parameters Based on NCI-CTCAE v4.03

    Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.

    Time frame: Up to Day 142

  4. Number of Participants With Grade Shift From Baseline in Electrolyte Parameters Based on NCI-CTCAE v4.03

    Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.

    Time frame: Up to Day 142

  5. Number of Participants With Grade Shift From Baseline in Coagulation Parameters Based on NCI-CTCAE v4.03

    Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.

    Time frame: Up to Day 142

  6. Number of Participants With Post-baseline Clinically Significant Urinalysis Abnormalities

    Clinical significance of abnormalities in urinalysis was determined based on the investigator's discretion. Baseline is defined as the last assessment prior to the randomization.

    Time frame: Up to Day 142

Secondary outcomes

  1. Percentage of Participants With Clinical Response

    Clinical response was based on the improvement of disease-specific signs and symptoms. Responders are defined as participants meeting all the following criteria: improvement of disease-specific signs and symptoms and no new signs, symptoms or complications attributable to the initial infection; No evidence of drainage, sinus tract formation or infection-related bone instability; No requirement for subsequent antibiotics with activity against Staphylococcus to treat the initial infection after the start of study treatment; Microbiological eradication of the baseline pathogen (if post-baseline sample\[s\] are available); Imaging test at 12 weeks post-EOT showing no worsening of baseline pathology or presence of signs indicating resolution or healing of the infection. Percentages are rounded off.

    Time frame: Part A: At Day 8, EOT (up to Day 22), 4-weeks post-EOT (up to Day 50), and 12-weeks post-EOT (up to Day 130); Part B: At Day 8, Day 28, Day 42, EOT (up to Day 43), 4-weeks post-EOT (up to Day 73), and 12-weeks post-EOT (up to Day 142)

07

Results

Posted Sep 9, 2026

Participant flow

Participants took part in the study at various investigative sites from 20 February 2019 to 23 April 2025.

Participant flow — Overall Study
MilestonePart A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2
Started8531182444
Completed8531141934
Not completed00004510
Withdrew: Adverse event00000100
Withdrew: Lost to follow-up00001100
Withdrew: Withdrawal of consent00001110
Withdrew: Participant unable to come to visit00002000
Withdrew: Participant withdrawn due to streptococcus report after randomization00000100
Withdrew: Screen failure00000100

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. TEAE is any undesirable event either not present prior to medical treatment or worsening (in intensity or frequency) following treatment. SAE is defined as any untoward medical occurrence that at any dose: results in death; is life-threatening (i.e., puts the patient at immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect, or is otherwise medically significant.

Time frame:
Up to Day 142
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPart A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2
TEAEs3300101723
SAEs01003410
PrimaryNumber of Participants With Grade Shift From Baseline in Hematology Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 4.03

Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.

Time frame:
Up to Day 142
Reported as:
Count of participants · Participants
Number of Participants With Grade Shift From Baseline in Hematology Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 4.03
ParticipantsPart A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2
Haemoglobin (High): Grade 0 (normal) to Grade 0 (normal)7531182242
Haemoglobin(High): Grade 0 (normal) to Grade 1 (high)10000002
Haemoglobin (Low): Grade 0 (normal) to Grade 0 (normal)41209233
Haemoglobin (Low): Grade 0 (normal) to Grade 1 (low)21005500
Haemoglobin (Low): Grade 0 (normal) to Grade 2 (low)00002100
Haemoglobin (Low): Grade 1 (low) to Grade 0 (normal)00000011
Haemoglobin (Low): Grade 1 (low) to Grade 1 (low)22101500
Haemoglobin (Low): Grade 1 (low) to Grade 2 (low)00010100
Haemoglobin (Low): Grade 2 (low) to Grade 1 (low)00000100
Haemoglobin (Low): Grade 2 (low) to Grade 2 (low)01001400
Haemoglobin (Low): Grade 2 (low) to Grade 3 (low)00000100
Haemoglobin (Low): Grade 3 (low) to Grade 3 (low)00000200
Leukocytes (High): Grade 0 (normal) to Grade 0 (normal)8531182244
Leukocytes (Low): Grade 0 (normal) to Grade 0 (normal)7431151944
Leukocytes (Low): Grade 0 (normal) to Grade 1 (low)11002300
Leukocytes (Low): Grade 1 (low) to Grade 0 (normal)00001000
Lymphocytes (High): Grade 0 (normal) to Grade 0 (normal)8530182144
Lymphocytes (High): Grade 0 (normal) to Grade 2 (high)00010100
Lymphocytes (Low): Grade 0 (normal) to Grade 0 (normal)5511121443
Lymphocytes (Low): Grade 0 (normal) to Grade 1 (low)20202100
Lymphocytes (Low): Grade 0 (normal) to Grade 2 (low)00001300
Lymphocytes (Low): Grade 1 (low) to Grade 0 (normal)00001001
Lymphocytes (Low): Grade 1 (low) to Grade 1 (low)10001000
Lymphocytes (Low): Grade 2 (low) to Grade 0 (normal)00001200
Lymphocytes (Low): Grade 2 (low) to Grade 1 (low)00000100
Lymphocytes (Low): Grade 3 (low) to Grade 0 (normal)00000100
Neutrophils (Low): Grade 0 (normal) to Grade 0 (normal)7431161843
Neutrophils (Low): Grade 0 (normal) to Grade 1 (low)10001300
Neutrophils (Low): Grade 0 (normal) to Grade 2 (low)01001001
Neutrophils (Low): Grade 0 (normal) to Grade 3 (low)00000100
Platelets (Low): Grade 0 (normal) to Grade 0 (normal)8531171933
Platelets (Low): Grade 0 (normal) to Grade 1 (low)00001311
PrimaryNumber of Participants With Grade Shift From Baseline in Clinical Chemistry Parameters Based on NCI-CTCAE v4.03

Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.

Time frame:
Up to Day 142
Reported as:
Count of participants · Participants
Number of Participants With Grade Shift From Baseline in Clinical Chemistry Parameters Based on NCI-CTCAE v4.03
ParticipantsPart A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2
Alanine Aminotransferase (High): Grade 0 (normal) to Grade 0 (normal)433181121
Alanine Aminotransferase (High): Grade 0 (normal) to Grade 1 (high)11008821
Alanine Aminotransferase (High): Grade 0 (normal) to Grade 2 (high)00000102
Alanine Aminotransferase (High): Grade 0 (normal) to Grade 4 (high)01001000
Alanine Aminotransferase (High): Grade 1 (high) to Grade 1 (high)30000200
Alanine Aminotransferase (High): Grade 1 (high) to Grade 2 (high)00001000
Alkaline Phosphatase (High): Grade 0 (normal) to Grade 0 (normal)6130101032
Alkaline Phosphatase (High): Grade 0 (normal) to Grade 1 (high)02017801
Alkaline Phosphatase (High): Grade 0 (normal) to Grade 2 (high)01000100
Alkaline Phosphatase (High): Grade 1 (high) to Grade 0 (normal)10000000
Alkaline Phosphatase (High): Grade 1 (high) to Grade 1 (high)11001311
Aspartate Aminotransferase (High): Grade 0 (normal) to Grade 0 (normal)7231121432
Aspartate Aminotransferase (High): Grade 0 (normal) to Grade 1 (high)02005511
Aspartate Aminotransferase (High): Grade 0 (normal) to Grade 2 (high)00000001
Aspartate Aminotransferase (High): Grade 0 (normal) to Grade 4 (high)01001000
Aspartate Aminotransferase (High): Grade 1 (high) to Grade 0 (normal)00000200
Aspartate Aminotransferase (High): Grade 1 (high) to Grade 1 (high)10000100
Aspartate Aminotransferase (High): Grade 1 (high) to Grade 2 (high)00000000
Bilirubin (High): Grade 0 (normal) to Grade 0 (normal)8431142033
Bilirubin (High): Grade 0 (normal) to Grade 1 (high)01002211
Bilirubin (High): Grade 0 (normal) to Grade 2 (high)00001000
Bilirubin (High): Grade 0 (normal) to Grade 3 (high)00001000
Creatine Kinase (High): Grade 0 (normal) to Grade 0 (normal)51319542
Creatine Kinase (High): Grade 0 (normal) to Grade 1 (high)230071001
Creatine Kinase (High): Grade 0 (normal) to Grade 2 (high)00001100
Creatine Kinase (High): Grade 0 (normal) to Grade 3 (high)00000100
Creatine Kinase (High): Grade 1 (high) to Grade 0 (normal)00000100
Creatine Kinase (High): Grade 1 (high) to Grade 1 (high)10000101
Creatine Kinase (High): Grade 1 (high) to Grade 2 (high)00000100
Creatine Kinase (High): Grade 1 (high) to Grade 3 (high)00001000
Creatine Kinase (High): Grade 2 (high) to Grade 1 (high)00000100
Creatine Kinase (High): Grade 2 (high) to Grade 2 (high)00000100
Creatine Kinase: Missing to Missing01000000
Creatinine (High): Grade 0 (normal) to Grade 0 (normal)7531151644
Creatinine (High): Grade 0 (normal) to Grade 1 (high)10002300
Creatinine (High): Grade 1 (high) to Grade 0 (normal)00000200
Creatinine (High): Grade 1 (high) to Grade 2 (high)00001100
Gamma Glutamyl Transferase (High): Grade 0 (normal) to Grade 0 (normal)5231131332
Gamma Glutamyl Transferase (High): Grade 0 (normal) to Grade 1 (high)10001311
Gamma Glutamyl Transferase (High): Grade 0 (normal) to Grade 2 (high)00002200
Gamma Glutamyl Transferase (High): Grade 0 (normal) to Grade 4 (high)01000000
Gamma Glutamyl Transferase (High): Grade 1 (high) to Grade 0 (normal)00000100
Gamma Glutamyl Transferase (High): Grade 1 (high) to Grade 1 (high)11001100
Gamma Glutamyl Transferase (High): Grade 1 (high) to Grade 2 (high)01001000
Gamma Glutamyl Transferase (High): Grade 2 (high) to Grade 2 (high)10000100
Gamma Glutamyl Transferase (High): Grade 2 (high) to Grade 3 (high)00000100
Gamma Glutamyl Transferase (High): Grade 3 (high) to Grade 3 (high)00000001
Glomerular Filtration Rate (Low): Grade 0 (normal) to Grade 0 (normal)62218922
Glomerular Filtration Rate (Low): Grade 0 (normal) to Grade 1 (low)22007201
Glomerular Filtration Rate (Low): Grade 0 (normal) to Grade 2 (low)00000100
Glomerular Filtration Rate (Low): Grade 1 (low) to Grade 0 (normal)00000010
Glomerular Filtration Rate (Low): Grade 1 (low) to Grade 1 (low)01102511
Glomerular Filtration Rate (Low): Grade 1 (low) to Grade 2 (low)00000200
Glomerular Filtration Rate (Low): Grade 2 (low) to Grade 1 (low)00000200
Glomerular Filtration Rate (Low): Grade 2 (low) to Grade 2 (low)00001100
Glucose (High): Grade 0 (normal) to Grade 0 (normal)433017631
Glucose (High): Grade 0 (normal) to Grade 1 (high)31012802
Glucose (High): Grade 0 (normal) to Grade 3 (high)00001000
Glucose (High): Grade 1 (high) to Grade 0 (normal)00000200
Glucose (High): Grade 1 (high) to Grade 1 (high)11002201
Glucose (High): Grade 1 (high) to Grade 2 (high)00000100
Glucose (High): Grade 2 (high) to Grade 1 (high)00000100
Glucose (High): Grade 2 (high) to Grade 2 (high)00000100
Glucose (High): Grade 3 (high) to Grade 1 (high)00000100
Glucose (High): Grade 3 (high) to Grade 3 (high)00000100
Glucose (Low): Grade 0 (normal) to Grade 0 (normal)8421161844
Glucose (Low): Grade 0 (normal) to Grade 1 (low)01101200
Glucose (Low): Grade 1 (low) to Grade 0 (normal)00001000
Glucose (Low): Grade 1 (low) to Grade 1 (low)00000200
Urate (High): Grade 0 (normal) to Grade 0 (normal)8531121641
Urate (High): Grade 0 (normal) to Grade 1 (high)00003302
Urate (High): Grade 1 (high) to Grade 0 (normal)00000100
Urate (High): Grade 1 (high) to Grade 1 (high)00003101
Urate (High): Grade 4 (high) to Grade 4 (high)00000100
PrimaryNumber of Participants With Grade Shift From Baseline in Electrolyte Parameters Based on NCI-CTCAE v4.03

Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.

Time frame:
Up to Day 142
Reported as:
Count of participants · Participants
Number of Participants With Grade Shift From Baseline in Electrolyte Parameters Based on NCI-CTCAE v4.03
ParticipantsPart A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2
Magnesium (High): Grade 0 (normal) to Grade 0 (normal)7421132244
Magnesium (High): Grade 0 (normal) to Grade 1 (high)00103000
Magnesium (High): Grade 0 (normal) to Grade 3 (high)01001000
Magnesium (High): Missing to Grade 0 (normal)00001000
Magnesium (High): Grade 1 (high) to Grade 1 (high)10000000
Magnesium (Low): Grade 0 (normal) to Grade 0 (normal)653161743
Magnesium (Low): Grade 0 (normal) to Grade 1 (low)20007301
Magnesium (Low): Grade 0 (normal) to Grade 2 (low)00000100
Magnesium (Low): Grade 0 (normal) to Grade 3 (low)00001000
Magnesium (Low): Missing to Grade 0 (normal)00001000
Magnesium (Low): Grade 1 (low) to Grade 1 (low)00001100
Magnesium (Low): Grade 3 (low) to Grade 3 (low)00001000
Magnesium (Low): Grade 3 (low) to Grade 4 (low)00001000
Potassium (High): Grade 0 (normal) to Grade 0 (normal)732181124
Potassium (High): Grade 0 (normal) to Grade 1 (high)01001320
Potassium (High): Grade 0 (normal) to Grade 2 (high)01104500
Potassium (High): Grade 0 (normal) to Grade 3 (high)00001000
Potassium (High): Grade 1 (high) to Grade 0 (normal)00001300
Potassium (High): Grade 1 (high) to Grade 1 (high)00002000
Potassium (High): Grade 2 (high) to Grade 0 (normal)10000000
Potassium (Low): Grade 0 (normal) to Grade 0 (normal)8531151722
Potassium (Low): Grade 0 (normal) to Grade 1 (low)00003412
Potassium (Low): Grade 1 (low) to Grade 3 (low)00000100
Potassium (Low): Grade 1 (low) to Grade 0 (normal)00000010
Sodium (High): Grade 0 (normal) to Grade 0 (normal)8431102232
Sodium (High): Grade 0 (normal) to Grade 1 (high)00004001
Sodium (High): Grade 0 (normal) to Grade 2 (high)00001000
Sodium (High): Grade 0 (normal) to Grade 4 (high)01000000
Sodium (High): Missing to Grade 0 (normal)00000001
Sodium (High): Grade 1 (high) to Grade 0 (normal)00000010
Sodium (High): Grade 1 (high) to Grade 1 (high)00002000
Sodium (High): Grade 1(high) to Grade 3 (high)00001000
Sodium (Low): Grade 0 (normal) to Grade 0 (normal)8431111923
Sodium (Low): Grade 0 (normal) to Grade 1 (low)01005220
Sodium (Low): Grade 0 (normal) to Grade 3 (low)00001000
Sodium (Low): Missing to Grade 0 (normal)00000001
Sodium (Low): Grade 1 (low) to Grade 0 (normal)00001100
Calcium, Ionized (High): Grade 0 (normal) to Grade 0 (normal)—————16—2
Calcium, Ionized (High): Grade 0 (normal) to Grade 1(high)—————1—0
Calcium, Ionized (High): Missing to Grade 0 (normal)—————1—0
Calcium, Ionized (Low): Grade 0 (normal) to Grade 0 (normal)—————15—2
Calcium, Ionized (Low): Grade 1 (low) to Grade 0 (normal)—————1—0
Calcium, Ionized (Low): Grade 1 (low) to Grade 2 (low)—————1—0
Calcium, Ionized (Low): Missing to Grade 1 (low)—————1—0
PrimaryNumber of Participants With Grade Shift From Baseline in Coagulation Parameters Based on NCI-CTCAE v4.03

Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.

Time frame:
Up to Day 142
Reported as:
Count of participants · Participants
Number of Participants With Grade Shift From Baseline in Coagulation Parameters Based on NCI-CTCAE v4.03
ParticipantsPart A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2
Activated Partial Thromboplastin Time (High): Grade 0 (normal) to Grade 0 (normal)4330101133
Activated Partial Thromboplastin Time (High): Grade 0 (normal) to Grade 1 (high)11014811
Activated Partial Thromboplastin Time (High): Grade 1 (high) to Grade 0 (normal)00003000
Activated Partial Thromboplastin Time (High): Grade 1 (high) to Grade 1(high)31001300
Prothrombin Intl. Normalized Ratio (High): Grade 0 (normal) to Grade 0 (normal)4520111243
Prothrombin Intl. Normalized Ratio (High): Grade 0 (normal) to Grade 1 (high)10104600
Prothrombin Intl. Normalized Ratio (High): Grade 0 (normal) to Grade 2 (high)00001001
Prothrombin Intl. Normalized Ratio (High): Grade 1 (high) to Grade 0 (normal)00010100
Prothrombin Intl. Normalized Ratio (High): Grade 1 (high) to Grade 1 (high)30002300
PrimaryNumber of Participants With Post-baseline Clinically Significant Urinalysis Abnormalities

Clinical significance of abnormalities in urinalysis was determined based on the investigator's discretion. Baseline is defined as the last assessment prior to the randomization.

Time frame:
Up to Day 142
Reported as:
Count of participants · Participants
Number of Participants With Post-baseline Clinically Significant Urinalysis Abnormalities
ParticipantsPart A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2
Number of Participants With Post-baseline Clinically Significant Urinalysis Abnormalities00000100
SecondaryPercentage of Participants With Clinical Response

Clinical response was based on the improvement of disease-specific signs and symptoms. Responders are defined as participants meeting all the following criteria: improvement of disease-specific signs and symptoms and no new signs, symptoms or complications attributable to the initial infection; No evidence of drainage, sinus tract formation or infection-related bone instability; No requirement for subsequent antibiotics with activity against Staphylococcus to treat the initial infection after the start of study treatment; Microbiological eradication of the baseline pathogen (if post-baseline sample\[s\] are available); Imaging test at 12 weeks post-EOT showing no worsening of baseline pathology or presence of signs indicating resolution or healing of the infection. Percentages are rounded off.

Time frame:
Part A: At Day 8, EOT (up to Day 22), 4-weeks post-EOT (up to Day 50), and 12-weeks post-EOT (up to Day 130); Part B: At Day 8, Day 28, Day 42, EOT (up to Day 43), 4-weeks post-EOT (up to Day 73), and 12-weeks post-EOT (up to Day 142)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response
percentage of participantsPart A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2
Day 887.5100100100100100100100
Day 28————077.3075.0
Day 42————04.500
EOT Visit10010010010010095.5100100
4 Weeks post-EOT Visit10010010010076.581.8100100
12 Weeks post-EOT Visit1008010010076.581.866.7100

Adverse events

Collected over Up to Day 142. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Afabicin: Cohort 10/8 (0%)0/8 (0%)3/8 (37.5%)
Part A: Afabicin: Cohort 20/5 (0%)1/5 (20%)3/5 (60%)
Part A: SoC: Cohort 10/3 (0%)0/3 (0%)0/3 (0%)
Part A: SoC: Cohort 20/1 (0%)0/1 (0%)0/1 (0%)
Part B: Afabicin: Cohort 10/18 (0%)3/18 (16.7%)10/18 (55.6%)
Part B: Afabicin: Cohort 21/22 (4.5%)4/22 (18.2%)18/22 (81.8%)
Part B: SoC: Cohort 10/4 (0%)1/4 (25%)2/4 (50%)
Part B: SoC: Cohort 20/4 (0%)0/4 (0%)3/4 (75%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPart A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2
Scar inflammationGeneral disorders0/80/50/30/10/180/221/40/4
Hepatic enzyme increasedInvestigations0/81/50/30/10/180/220/40/4
Acute hepatitis CInfections and infestations0/80/50/30/11/180/220/40/4
Post procedural infectionInfections and infestations0/80/50/30/11/180/220/40/4
Limb injuryInjury, poisoning and procedural complications0/80/50/30/11/180/220/40/4
Arthritis bacterialInfections and infestations0/80/50/30/10/181/220/40/4
Device related infectionInfections and infestations0/80/50/30/10/181/220/40/4
Urinary tract infectionInfections and infestations0/80/50/30/10/181/220/40/4
Complication associated with deviceGeneral disorders0/80/50/30/10/181/220/40/4
ArthralgiaMusculoskeletal and connective tissue disorders0/80/50/30/10/181/220/40/4
Most frequent other events
Showing 10 of 64
Most frequent other events
EventPart A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2
Alanine aminotransferase increasedInvestigations1/80/50/30/13/181/220/43/4
Aspartate aminotransferase increasedInvestigations0/80/50/30/13/181/220/42/4
Hepatic enzyme increasedInvestigations0/82/50/30/10/180/220/40/4
Blood creatine phosphokinase MB increasedInvestigations0/80/50/30/11/180/221/40/4
SARS-CoV-2 test positiveInvestigations0/80/50/30/10/180/221/40/4
Vitamin B12 deficiencyMetabolism and nutrition disorders0/80/50/30/10/180/220/41/4
Scar inflammationGeneral disorders0/80/50/30/10/180/221/40/4
TachycardiaCardiac disorders0/80/50/30/10/180/220/41/4
HypotensionVascular disorders0/80/50/30/10/180/220/41/4
AnaemiaBlood and lymphatic system disorders0/80/50/30/10/185/220/40/4

Baseline characteristics

Safety analysis set included all randomized participants who received at least one dose of any study drug. As pre-specified in the protocol, ethnicity data was not collected in this study.

Age, Continuous
Age, Continuous(years)Part A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2Total
Mean44.8 ± 8.1255.0 ± 5.5755.0 ± 1.7354.0 ± NA43.1 ± 12.8755.0 ± 16.7546.8 ± 10.7247.8 ± 13.0549.5 ± 13.73
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2Total
Female2110162114
Male642117162351
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Afabicin: Cohort 1Part A: Afabicin: Cohort 2Part A: SoC: Cohort 1Part A: SoC: Cohort 2Part B: Afabicin: Cohort 1Part B: Afabicin: Cohort 2Part B: SoC: Cohort 1Part B: SoC: Cohort 2Total
American Indian or Alaska Native000000000
Asian000001001
Native Hawaiian or Other Pacific Islander000000000
Black or African American000002024
White853118194260
More than one race000000000
Unknown or Not Reported000000000
08

Study locations

19 sites
  • Georgian Clinics JSC
    Akhalts'ikhe, 0800, Georgia
  • West Georgia Medical Center LLC
    Kutaisi, 4600, Georgia
  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC
    Tbilisi, 0101, Georgia
  • LEPL The First University Clinic of Tbilisi State Medical University
    Tbilisi, 0141, Georgia
  • Tbilisi State Medical University And Ingorokva High Medical Technology University Clinic LLC
    Tbilisi, 0144, Georgia
  • Academician Vakhtang Bochorishvili Clinic LTD
    Tbilisi, 0160, Georgia
  • Caucasus Medical Center LLC
    Tbilisi, 0186, Georgia
  • Worthwhile Clinical Trials, Lakeview Hospital
    Benoni, 1500, South Africa
  • Clinical Research Unit, University of Pretoria
    Pretoria, 0002, South Africa
  • Global Clinical Trials (Pty) Ltd
    Pretoria, 0157, South Africa
  • Dnipropetrovsk Regional Clinical Hospital
    Dnipro, 49027, Ukraine
  • Regional Clinical Hospital under Ivano-Frankivsk Regional Council
    Ivano-Frankivsk, 76008, Ukraine
  • Kharkiv Regional Clinical Traumatology Hospital
    Kharkiv, 61176, Ukraine
  • Institute of Traumatology and Orthopedics
    Kyiv, 01601, Ukraine
  • Kyiv Regional Clinical Hospital
    Kyiv, 04107, Ukraine
  • Kyiv City Clinical Hospital #8 under the Executive Body of Kyiv City Council (Kyiv City State Administration)
    Kyiv, Ukraine
  • Vinnytsya Regional Clinical Hospital
    Vinnytsia, 21028, Ukraine
  • Lviv Regional Hospital of Veterans of Wars and Repressed after Yurii Lypa
    Vynnyky, 79495, Ukraine
  • City Hospital #9 under Zaporizhia City Council
    Zaporizhia, 69065, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Apr 2025, 74 months.

Results were first posted in Sep 2026, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2018
First posted
Oct 29, 2018
StartActual
Feb 20, 2019
Primary completionActual
Apr 23, 2025
CompletionActual
Apr 23, 2025
Results first posted
Sep 9, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03723551
Responsible party
Sponsor
First posted
Oct 29, 2018
Start date
Feb 20, 2019
Primary completion
Apr 23, 2025
Completion
Apr 23, 2025
Results posted
Sep 9, 2026
Last update
Sep 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afabicin

Start the discussion